The earnings call presents a balanced view with significant achievements in clinical trial progress and strategic amendments to enhance regulatory approval processes. However, financial challenges and a temporary trial pause highlight ongoing operational and funding hurdles.

Company Guidance

During the call, PDS Biotechnology Corporation provided guidance on their clinical trials and financial performance. They announced the completion of the VERSATILE-002 trial, highlighting a median overall survival (MOS) of 39.3 months for patients with a combined positive score (CPS) of ≥1, and a progression-free survival (PFS) of 10.3 months in the same group. The decision to amend the VERSATILE-003 trial to include PFS as a primary endpoint alongside MOS was discussed, with a meeting requested with the FDA to finalize this amendment. Financially, the company reported a net loss of $9 million for Q3 2025, a decrease from the previous year's $10.7 million, attributed to lower operating expenses. They closed the quarter with a cash balance of $26.2 million, down from $41.7 million at the start of the year.

Completion of VERSATILE-002 Trial

The VERSATILE-002 trial was completed, showing a median overall survival of 39.3 months for patients with HPV16 positive head and neck cancer, significantly higher than historical data.

Amendment to VERSATILE-003 Trial

A strategic decision was made to amend the VERSATILE-003 trial to include progression-free survival as a primary endpoint, potentially accelerating regulatory submission.

Positive Financial Adjustments

The net loss decreased to $9 million from $10.7 million in the prior year, primarily due to lower operating expenses.

Industry Recognition and External Validation

PDS Biotechnology's approach was validated by multiple clinical investigators and institutions, with significant interest in the rapidly growing HPV16 positive head and neck cancer market.

PDS Biotechnology (PDSB) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

PDSB Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Mar 26, 2026	2025 (Q4)	-0.18 / -	-0.21	―	―	―
Nov 13, 2025	2025 (Q3)	-0.20 / -0.19	-0.29	34.48% (+0.10)	―
Aug 13, 2025	2025 (Q2)	-0.23 / -0.21	-0.23	8.70% (+0.02)	―
May 14, 2025	2025 (Q1)	-0.25 / -0.21	-0.3	30.00% (+0.09)	―
Mar 27, 2025	2024 (Q4)	-0.28 / -0.21	-0.35	40.00% (+0.14)	―
Nov 14, 2024	2024 (Q3)	-0.30 / -0.29	-0.35	17.14% (+0.06)	―
Aug 13, 2024	2024 (Q2)	-0.33 / -0.23	-0.37	37.84% (+0.14)	―	―
May 15, 2024	2024 (Q1)	-0.37 / -0.30	-0.32	6.25% (+0.02)	―	―
Mar 27, 2024	2023 (Q4)	-0.44 / -0.35	-0.65	46.15% (+0.30)	―
Nov 14, 2023	2023 (Q3)	-0.45 / -0.35	-0.26	-34.62% (-0.09)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

PDSB Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Nov 13, 2025	$0.96	$0.84	-12.50%
Aug 13, 2025	$1.23	$1.16	-5.69%
May 14, 2025	$1.27	$1.31	+3.15%
Mar 27, 2025	$1.24	$1.25	+0.81%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does PDS Biotechnology Corporation (PDSB) report earnings?

PDS Biotechnology Corporation (PDSB) is schdueled to report earning on Mar 26, 2026, TBA (Confirmed).

What is PDS Biotechnology Corporation (PDSB) earnings time?

PDS Biotechnology Corporation (PDSB) earnings time is at Mar 26, 2026, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is PDSB EPS forecast?

PDSB EPS forecast for the fiscal quarter 2025 (Q4) is -0.18.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing